Optimization of the immunization protocol, for example by inclusion of adjuvants such as CpGs or antibodies against checkpoint inhibitors in combination with adoptive T cell transfer [27–29], might further improve this protective effect, providing the basis for preclinical immunotherapy studies in this NY-BR-1 expressing tumor model. Here, ANKRD30A is linked to neoplasm.